Drugs / Ig NextGen 10%
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00362349 | Jun 2007 → Oct 2008 | autoimmune thrombocytopenic purpura | CSL Limited | Completed | No outcome recorded |
| Phase 3 | NCT00405184 | May 2007 → Jul 2008 | immunodeficiency disease | CSL Limited | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ig NextGen 10% | “Ig NextGen 10% is a liquid formulation” NCT00362349 ↗ |
| Known as | Intragam 10 NF | “Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies.” PMID 22212346 ↗ Mar 2012 |
| Modality | Protein / enzyme biologic | “Intravenous Immunoglobulin (IVIg) therapy” NCT00362349 ↗ |
| Route | Intravenous | “administered intravenously” NCT00362349 ↗ |